CLVS
Price:
$0.0812
Market Cap:
$0
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through ...[Read more]
Industry
Biotechnology
IPO Date
2011-11-16
Stock Exchange
NASDAQ
Ticker
CLVS
According to Clovis Oncology, Inc.’s latest financial reports and current stock price. The company's current ROE is 120.90%. This represents a change of 538.55% compared to the average of 18.93% of the last 4 quarters.
The mean historical ROE of Clovis Oncology, Inc. over the last ten years is 958.12%. The current 120.90% ROE has changed -87.38% with respect to the historical average. Over the past ten years (40 quarters), CLVS's ROE was at its highest in in the December 2016 quarter at 1.95%. The ROE was at its lowest in in the March 2019 quarter at -115.46%.
Average
958.12%
Median
-32.62%
Minimum
-251.25%
Maximum
9.61%
Discovering the peaks and valleys of Clovis Oncology, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 184.22%
Maximum Annual ROE = 9.61%
Minimum Annual Increase = -8285.94%
Minimum Annual ROE = -251.25%
Year | ROE | Change |
---|---|---|
2021 | 94.87% | -59.21% |
2020 | 232.58% | 1.21% |
2019 | 229.79% | -191.46% |
2018 | -251.25% | 166.66% |
2017 | -94.22% | -100.98% |
2016 | 9.61% | -8285.94% |
2015 | -117.37% | 143.22% |
2014 | -48.26% | 184.22% |
2013 | -16.98% | -69.36% |
2012 | -55.42% | 31.44% |
The current ROE of Clovis Oncology, Inc. (CLVS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
185.74%
5-year avg
42.35%
10-year avg
958.12%
Clovis Oncology, Inc.’s ROE is
Company | ROE | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Clovis Oncology, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Clovis Oncology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Clovis Oncology, Inc.'s ROE?
How is the ROE calculated for Clovis Oncology, Inc. (CLVS)?
What is the highest ROE for Clovis Oncology, Inc. (CLVS)?
What is the 3-year average ROE for Clovis Oncology, Inc. (CLVS)?
What is the 5-year average ROE for Clovis Oncology, Inc. (CLVS)?
How does the current ROE for Clovis Oncology, Inc. (CLVS) compare to its historical average?